Government Licenses Viral Peptide to Fight Liver Cancer
Published Date: 7/2/2026
Notice
Summary
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Potential New HCC Vaccine/Therapy
Researchers at the NCI report that a synthetic CE1 peptide can elicit T cell responses against HCC cells and could be developed as an immunotherapy or CE1-based HCC vaccine. The notice says such novel treatments could offer substantial public health benefits for people at risk of or living with hepatocellular carcinoma worldwide.
NIH Offers CE1 Peptide License
The National Cancer Institute (NCI) is offering a license and co-development opportunities for a viral peptide (CE1) intended for hepatocellular carcinoma (HCC) prevention and treatment (NIH Reference Number E-023-2024). The technology is at the Discovery stage and is being offered for commercial development; a related patent application (PCT/US2025/059785) was filed December 16, 2025.
New Diagnostic and Monitoring Uses
The NCI lists potential commercial applications including a predictive biomarker for HCC risk, a serological response test, patient stratification for CE1-based therapy, and tools to monitor vaccine efficacy. These applications could be developed and licensed for clinical use alongside CE1-based therapeutics.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Previous / Next Documents
Previous: 2026-13479, Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Next: 2026-13486, Implementing Voluntary Agreements Under the Defense Production Act
The Department of Energy is rolling out a new voluntary agreement to boost the U.S. nuclear fuel supply chain, helping keep energy secure and strong. This affects companies in the nuclear fuel cycle, encouraging teamwork without forcing anyone. The plan kicks in after October 2025 and aims to support national security while keeping energy flowing smoothly.